12 registrations that name taurine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 12 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 12 registrations
RecruitingNCT07654946
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
No phase
Louisiana State University and A&M College
About 34 people
Started Jul 15, 2026
In plain words A study of taurine in people 18 to 40, run by Louisiana State University and A&M College. It plans to enroll about 34 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Local Muscular Endurance and Fatigue; NIRS Skeletal Muscle Mitochondrial Capacity; Acute Taurine Supplementation.
Capable and willing to give written informed consent
Capable of understanding inclusion and exclusion criteria
No medical condition that would limit participation in supervised exercise
No current prescription medications known to impact mitochondrial function
2 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this clinical trial is to determine the association between near-infrared spectroscopy (NIRS)-derived mitochondrial oxidative phosphorylation (OXPHOS) capacity of the vastus lateralis muscles, and both local muscular endurance capacity and local muscular fatigability of the thigh muscles in young adults. Additionally, this trial aims to determine the effect of acute taurine supplementation on local muscular endurance capacity and local muscular fatigability when compared to a placebo condition. The main questions it aims to answer are: 1. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07212803
Effects of Energy Drinks on Cardiovascular Endpoints
Phase 4
University of the Pacific
About 3 people
Started Nov 1, 2025
In plain words A Phase 4 study of taurine in people 18 to 40, run by University of the Pacific. It plans to enroll about 3 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Healthy Volunteers; Safety After Oral Intake.
Healthy male or female adults 18-40 years of age
Female participants of child-bearing potential must have a negative pregnancy test at the baseline visit
Participants must be willing to refrain from caffeine and alcohol use 72 hours prior to sessions on study days
Participants must be willing and able to: (1.) Consume up to 1 liter of fluid within a 30-minute period per visit (2.) Swallow a single large capsule per visit
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Energy Drink A + Placebo Capsule; Placebo Drink + Moxifloxacin Capsule; Placebo Drink + Caffeine Capsule; Placebo Drink + Placebo Capsule; Energy Drink B; Control Product + Taurine; Control Product + Caffeine + Taurine; Lower Dose Energy Drink A
Registered summary
This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.
Where, as registered
1 US site in 1 state.
RecruitingNCT06721949
Taurine Supplementation in Long COVID
Phase 2 and 3
University of Alberta
About 300 people
Started Nov 18, 2025
In plain words A Phase 2 and 3 study of taurine in people 18 and older, run by University of Alberta. It plans to enroll about 300 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Long COVID.
Age ≥18 years;
Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after…
If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).
Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Taurine; Placebo
Registered summary
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. The full summary is on the listing.
Where, as registered
No US site; Canada (5).
RecruitingNCT07029178
Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis
Phase 2
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
About 160 people
Started Nov 24, 2025
In plain words A Phase 2 study of taurine in people 18 to 80, run by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. It plans to enroll about 160 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Radiation Induced Oral Mucositis; Radiodermatitis.
Patients voluntarily joined the study, were informed of the purpose and process of the study, signed the informed consent form, and were willing and able to abide by the study protocol.
Aged 18 to 80, with no gender restrictions.
Patients that require radiotherapy after surgery for oral/oropharyngeal cancer. After evaluation by the radiation oncologist, radiotherapy at 30 sessions /60Gy is planned.
The expected survival period is more than 6 months.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Taurine granule; Placebo granule
Registered summary
This is a single-center, double-blind, randomized controlled study. The patients were divided into control group and experimental group, 80 cases each. From the first day of radiotherapy to the end of radiotherapy, the experimental group was treated with 24 grams of taurine granule (containing 4.8 grams of taurine) before each day's radiotherapy. The control group was treated with the same amount of placebo.
Where, as registered
No US site; China (1).
RecruitingNCT06128252
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
No phase
Tang-Du Hospital
About 96 people
Started Sep 1, 2024
In plain words A study of taurine in people 18 to 75, run by Tang-Du Hospital. It plans to enroll about 96 people at 15 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Gastric Cancer.
Age 18-75 years old, no gender limitation;
Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with cTNM stage II/III，T≥3, N ≥0, M=0；
Expected survival of ≥ 3 months;
The tumor specimens were PD-L1 positive (CPS ≥ 1)；
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Taurine; Serplulimab; XELOX regimen; Placebo
Registered summary
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.
Where, as registered
No US site; China (15).
RecruitingNCT07710547
TCP-600 Supplementation and Performance Response in Professional Football Players
No phase
Vizja University in Warsaw
About 65 people
Starts Sep 2026 (estimated)
In plain words A study of taurine in male participants 18 to 37, run by Vizja University in Warsaw. It plans to enroll about 65 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 37; healthy volunteers accepted. Conditions: Athletic Performance; Cognitive Fatigue; Exercise Recovery; Football-Specific Performance; Perceptual-cognitive Performance.
Male professional or highly trained football players aged 18-37 years.
Regular participation in structured football training and team activities.
Minimum of 5 years of structured football training experience.
Regular involvement in club training during the study period.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Taurine; Caffeine; Phosphatidylserine
Registered summary
This study will examine whether a 28-day supplementation protocol containing taurine, caffeine, and phosphatidylserine can help professional male football players maintain physical performance, cognitive function, recovery-related readiness, and selected football-specific perceptual-cognitive performance. Participants will be randomly assigned to receive either placebo or a phosphatidylserine-containing multi-ingredient supplement. The full summary is on the listing.
Where, as registered
No US site; Poland (3).
RecruitingNCT07312409
Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?
Observational
York University
About 30 people
Started Jun 1, 2026
In plain words An observational study of taurine in people 18 to 65, run by York University. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Long COVID Syndrome.
Participants will have had symptoms of Long COVID post-infection for at least 3 months
The exclusion criteria are on the listing.
What it tests, as registered
Taurine supplementation
Registered summary
Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio/cerebrovascular responses to upright posture. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07487623
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
No phase
University of Guadalajara
About 26 people
Started Oct 11, 2025
In plain words A study of taurine in people 18 to 69, run by University of Guadalajara. It plans to enroll about 26 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 69. Conditions: Liver Disease Chronic; HEPATITIS C VIRUS CHRONIC INFECTION.
What it tests, as registered
resveratrol, quercetin, taurine, whey protein, and inulin; whey protein
Registered summary
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection. The study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment. The full summary is on the listing.
Where, as registered
No US site; Mexico (2).
Not yet recruitingNCT07144033
Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients
No phase
Chinese University of Hong Kong
About 216 people
Starts Jan 1, 2026 (estimated)
In plain words A study of taurine in people 18 and older, run by Chinese University of Hong Kong. It plans to enroll about 216 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pain, Acute; Pain, Chronic; Chronic Post Operative Pain.
Adult patients aged 18 or older
elective surgery
coronary artery bypass graft (CABG), valve repair/replacement, combined CABG/valve procedure, or major aortic procedure via sternotomy
The exclusion criteria are on the listing.
What it tests, as registered
Butyrate and Taurine; Placebo
Registered summary
This study is a single-center, phase II, randomized, placebo-controlled, Bayesian-designed, double-blinded trial Goal and Questions: The primary goal is to evaluate if a combination of taurine and butyrate can reduce chronic postsurgical pain (CPSP) in adult cardiac surgical patients. The study also aims to determine if these compounds are safe, effective in perioperative pain control, and feasible for improving postoperative outcomes. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
Not yet recruitingNCT07567742
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Phase 2
Sun Yat-sen University
About 130 people
Starts May 6, 2026 (estimated)
In plain words A Phase 2 study of taurine in people 18 to 70, run by Sun Yat-sen University. It plans to enroll about 130 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Oral Mucositis (Ulcerative) Due to Radiation; Nasopharyngeal Carcinoma (NPC).
Non-metastatic nasopharyngeal carcinoma (Stage I-III) according to the AJCC 9th edition staging system.
Scheduled to receive radical intensity-modulated radiotherapy (IMRT).
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Taurine
Registered summary
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07682402
Taurine Supplementation in Adolescents With Post-COVID Condition
Phase 1 and 2
University of Alberta
About 30 people
Starts Dec 30, 2026 (estimated)
In plain words A Phase 1 and 2 study of taurine in people 10 to 17, run by University of Alberta. It plans to enroll about 30 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 17. Conditions: Long COVID; Post COVID-19 Condition; PASC Post Acute Sequelae of COVID 19.
Subjects must be between 10 and 17 years of age at the time of study enrollment
Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15,…
If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).
Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Taurine
Registered summary
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07656051
Taurine and Nitrate Supplementation on Thermoregulatory in T2DM
No phase
University of Portsmouth
About 18 people
Starts Jun 1, 2026 (estimated)
In plain words A study of taurine in people 35 and older, run by University of Portsmouth. It plans to enroll about 18 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 35 and older. Conditions: Type 2 Diabetes.
Male or female (post-menopausal) aged 35 years or above.
Diagnosed with T2DM as defined by the WHO (HbA1c ≥48 mmol/mol).
Willing and able to give informed consent for participation in the study.
Able to understand and fully cooperate with the study protocol.
The exclusion criteria are on the listing.
What it tests, as registered
taurine; Beetroot and taurine; Placebo
Registered summary
Anthropogenic warming is increasing the frequency and intensity of extreme heat events. Elevated temperatures raise the risk of mortality and hospital admissions, particularly among people with chronic illnesses such as type 2 diabetes mellitus (T2DM). Globally, around 530 million people live with T2DM , and in the United Kingdom nearly six million are affected, creating a substantial population vulnerable to heat related illness. The full summary is on the listing.